Certara $CERT: Biosimulation, Growth and Cash Flow

01 Three scenarios: can a simpler company produce better growth?

The constructive case for Certara is that a more focused portfolio and improved commercial execution turn a valuable scientific position into a stronger financial record. The business provides software and services used in drug discovery and development. It does not need to own a successful drug to benefit from customers’ use of those tools. In the favorable scenario, software adoption expands, existing customers renew or broaden their use, and services activity improves without requiring disproportionate growth in the cost base. A cleaner portfolio would then make both execution and financial interpretation easier.

The middle scenario is a slower transition. Software grows, but services remain sensitive to customers’ development budgets and project timing. Cost reductions help preserve profitability measures while revenue growth remains modest. Under this outcome, the company may become operationally simpler without immediately achieving the growth profile suggested by its scientific importance. That would not make the technology irrelevant. It would mean that customer value, pricing power and shareholder returns are moving at different speeds. A credible platform can still need time to improve its commercial performance.

The adverse scenario is that organizational change and capital allocation fail to solve the underlying demand problem. Services could remain weak, software bookings could slow, and investment in products or artificial intelligence could fail to generate an adequate return. A disposal can remove revenue and complexity, but it cannot guarantee better growth in the retained business. Similarly, share repurchases can reduce the denominator without improving the economic quality of the numerator. Under this scenario, reported adjusted profitability could coexist with limited free cash generation and an unconvincing growth trajectory.

The evidence that would distinguish these outcomes is specific: comparable continuing-operations growth, software and services bookings, conversion of bookings into revenue, cash generation after product investment, and the cost of restructuring. No probability or share-price target is assigned here. A precise target would require assumptions about growth, margins, capital intensity and the appropriate valuation multiple that are not established by a single quarter. The aim is to identify which operating developments matter and to avoid treating a scientific narrative as a completed financial turnaround.

The assessment would improve if the company demonstrated sustained software growth alongside stabilization in services and better cash conversion. It would weaken if bookings failed to become revenue, if adjustments repeatedly obscured weak underlying economics, or if repurchases consumed cash needed for the product roadmap and balance sheet. The central question is whether the simplified company earns a better return on its capabilities. A change in structure is a starting point for that test, not the result. Sources: Q2 Sec, Q2 Release, Annual Sec.

02 What Certara does: tools and expertise across drug development

Certara, Inc. is headquartered in Radnor, Pennsylvania, and its common stock trades on Nasdaq as CERT. The business combines scientific software with technology-enabled services supporting drug discovery, development and regulatory work. Biosimulation is central to that offering: models are used to help understand how a drug behaves, how exposure relates to response and how development decisions might be improved. The company earns from software and service delivery, rather than relying on one proprietary drug’s approval or commercial launch. Sources: Annual Sec, Q2 Sec.

This distinction matters for risk analysis. A drug developer can face a binary outcome around a pivotal study or regulatory decision for its main asset. Certara has exposure to many customers and programs, but it also depends on their willingness and ability to fund development work. Diversification across projects reduces dependence on any one drug while leaving the company exposed to broader research budgets, project cancellations and procurement decisions. A difficult funding environment for smaller biotechnology companies can therefore affect a tools provider even when its own technology remains useful.

The annual filing describes products including Simcyp, Phoenix, Pinnacle 21 and discovery-oriented software. These products address different parts of the workflow. They should not be described as a single interchangeable platform or as one product with uniform revenue economics. Some work involves models and simulation; some supports data standards or informatics. The scientific capabilities can reinforce one another, but a financial analysis still needs to distinguish product adoption, service delivery and the costs of developing and supporting each offering. Source: Annual Sec.

Certara’s value proposition is that better evidence and better decisions can improve the efficiency of development. That does not mean every use of a model replaces a clinical trial. Whether modeling can support a particular decision depends on the question, the data, the model’s credibility and the relevant regulatory expectations. A case study can demonstrate a useful application without establishing that all development work can move to software. The stronger commercial interpretation is a role in an increasingly evidence-intensive process, with opportunities that must be converted into paying use.

The business is therefore best evaluated as a scientific software and services company with healthcare exposure. Its operating measures should include customer demand, bookings, revenue mix, margins, product investment and cash conversion. A biotechnology catalyst calendar may still provide context for its customers, but Certara itself should not be assigned a fictitious PDUFA date. Its principal near-term tests are business execution and financial results, not approval of a Certara-owned therapeutic product.

03 Biosimulation: why the science matters without guaranteeing the stock thesis

Biosimulation uses quantitative models to explore biological and pharmacological questions. In drug development, a model can help organize existing evidence, compare possible dosing strategies or investigate how patient characteristics could affect drug exposure. Certara’s annual report describes both mechanistic and empirical approaches in its software and services. Those approaches are complementary, but their usefulness depends on the question and the quality of the supporting data. The existence of a sophisticated model is not itself proof that a prediction is appropriate for every clinical decision. Source: Annual Sec.

The scientific value of modeling can be substantial when it helps a development team avoid an uninformative experiment or make a better-supported choice. From a commercial perspective, however, that value still has to be captured through pricing, licenses, service engagements or broader customer adoption. A tool may save a customer time while the vendor experiences only modest revenue growth. This gap between customer value and vendor economics is a recurring theme in software businesses and is particularly relevant when a specialized product becomes deeply embedded in a workflow.

Regulatory use can strengthen credibility because development teams care about whether their evidence will be interpretable and acceptable in a submission. But regulatory familiarity is not a perpetual endorsement of every product version or every use case. It also does not remove competition. Customers may use internal expertise, alternative software or different modeling approaches. The economic advantage must therefore be maintained through scientific quality, usability, support and integration with the rest of the development workflow.

Certara’s March 2026 Simcyp announcement described a specific application involving asciminib and model-based evidence accepted by regulators. That case illustrates why the technology can matter, but it should remain a case study. It does not establish that future projects will receive the same treatment, that all conventional trials are unnecessary, or that the case produced a separately disclosed revenue amount for Certara. The announcement supports the scientific relevance of the product, not a numerical forecast for the company’s sales. Source: Simcyp.

For an investor, the most informative combination is scientific relevance plus evidence of repeatable commercial demand. Product announcements should eventually connect to customer adoption, bookings and revenue. If the scientific narrative strengthens while the commercial measures do not, the analytical question is where the conversion is failing: budget constraints, pricing, competition, sales execution or the time needed for adoption. This is a more useful inquiry than assuming that an important scientific tool must automatically produce a high-growth stock.

04 Software and services: two revenue streams with different operating behavior

For the second quarter ended June 30, 2026, Certara reported continuing-operations revenue of $93.3 million. Software contributed $48.8 million and services $44.5 million. The company reported year-over-year software growth of 4% and a services decline of 3%. These figures describe the retained business on a comparable continuing-operations basis. They should not be mixed with older consolidated revenue totals that included the divested Regulatory and Medical Writing business. Sources: Q2 Release, Q2 Sec.

Software and services have different cost and timing characteristics. A software product can require substantial development investment before additional sales are delivered at relatively low incremental cost. Services require appropriately skilled people to perform work, and utilization can affect profitability when customer demand moves. Both businesses can generate valuable customer relationships, but a dollar of revenue does not necessarily carry the same margin or cash profile in each. A change in mix can therefore alter profitability even when total revenue growth looks small.

Services can also support software adoption. Experts may help customers apply a tool to a difficult development question, increasing the product’s practical usefulness. Conversely, software can make service delivery more efficient. That relationship creates a plausible integrated business model, but it does not remove the need to measure each activity. Cross-selling should be demonstrated through customer behavior and financial performance, not assumed merely because both offerings sit inside one organization.

The current split makes the operating question clear. Software growth is constructive, but it has not yet produced strong consolidated growth because services weakness offsets part of the gain. A recovery in services would change the overall picture; a slowdown in software would weaken it. Readers should therefore resist describing the company as either a pure software growth story or a conventional consulting business. The financial result depends on the interaction between the two, including their mix and the level of investment needed to support them.

Future disclosures should be compared on the same basis and with the same definitions. Acquisitions, divestitures, currency movements and changes in classification can affect apparent growth. A reported percentage is useful only if its denominator is understood. This hub uses the company’s continuing-operations comparisons for the current quarter and treats the annual report as context for the business, not as an automatically comparable revenue base. That discipline is particularly important during the first reporting periods after a major disposal.

05 The 2026 disposal: a simpler portfolio with a real accounting cost

Certara completed the sale of its Regulatory and Medical Writing business to Veristat on May 8, 2026. The June-quarter filing reports $69.435 million of cash consideration received, $15 million placed in escrow subject to conditions and a potential earn-out of up to $35 million. The escrow and earn-out are not the same as cash already collected. The filing also records an estimated pretax loss on sale of $65.481 million, with an estimated after-tax loss of $48.576 million. Source: Q2 Sec, Note 4.

The strategic case for the disposal is focus. A company can become easier to manage when leadership and investment concentrate on activities that fit the core product and service proposition. The cost is that a disposed business no longer contributes its future revenue and earnings, while some overhead may remain. A sale therefore needs to be evaluated through both the proceeds and the economics of the retained company. A higher growth rate after removing a slower activity may be helpful, but it is not by itself proof of better total value creation.

The accounting presentation is essential. The divested business is reported as discontinued operations, and comparable periods are restated on that basis. The Q2 earnings release’s $6.1 million loss refers to continuing operations. The consolidated income statement reports a much larger total net loss of $55.270 million after discontinued operations, including the disposal effect. These are not conflicting accounts. They answer different questions. Presenting the smaller figure without its scope would understate the quarter’s total GAAP loss; presenting only the larger figure could hide the retained business’s operating trend. Sources: Q2 Release, Q2 Sec.

A transition-services agreement adds another layer. Such arrangements can allow a buyer to use specified administrative or technology services while systems are separated. They do not mean that the sold business remains a normal part of the seller’s portfolio. They can, however, create temporary costs, revenue or operational obligations. The relevant question is how quickly the retained company reaches its intended steady-state cost structure and whether stranded costs are actually removed.

The disposal should therefore be treated as a completed transaction with continuing consequences. The sale date and cash receipt are facts; the eventual escrow and earn-out realization remain conditional; and the improvement in the retained company’s economics remains an execution test. A clean analytical bridge preserves all three. It avoids the temptation to describe the transaction solely as a positive simplification or solely as a loss. The evidence supports a portfolio change whose ultimate value depends on what management does with the proceeds and the remaining business.

06 Quarterly profitability: adjusted EBITDA is useful, but it is not cash

The second-quarter release reports adjusted EBITDA of $26.2 million, compared with $27.0 million a year earlier, alongside the $6.1 million continuing-operations net loss. The company provides a reconciliation of its non-GAAP measures to GAAP results. Adjusted EBITDA can help compare operations across periods affected by acquisition accounting and other specified items. It should not be substituted for net income or cash flow, because it excludes expenses and cash requirements that can matter to shareholders. Source: Q2 Release.

The most useful approach is to read the reconciliation as an explanation rather than as permission to ignore the excluded items. Depreciation and amortization may be noncash in the current quarter, but the assets or acquired businesses were not necessarily free. Equity compensation may not consume current cash, but it can affect the shareholder denominator. Reorganization charges may support future savings, but repeated charges can become a persistent cost of running the business. Each adjustment needs an economic interpretation.

Year-over-year comparisons also need care when the prior period benefited from a favorable contingent-consideration adjustment. The absence of such a benefit can make the new period look weaker even if that particular change does not reflect deteriorating customer demand. Conversely, removing an unfavorable item from adjusted results does not demonstrate that every aspect of the business improved. A good comparison separates operating trends, acquisition-related accounting and changes in the cost base, rather than compressing them into one number.

Margins should be considered with growth and investment. A company can improve a margin by reducing costs while revenue remains weak, but excessive cuts could compromise the product roadmap or service quality. A company can also accept near-term margin pressure to fund valuable product development, though that rationale must eventually be tested against outcomes. The right balance cannot be inferred from the direction of a single percentage. It depends on whether spending supports a credible path to sustainable customer demand and cash returns.

For Certara, the next test is whether the retained business can combine modest current growth with the benefits management expects from organizational change. Stronger adjusted profitability would be more convincing if it were accompanied by comparable revenue growth, healthy bookings and improved cash generation after software development investment. Without those connections, adjusted EBITDA risks becoming an isolated metric. The hub therefore keeps GAAP results, non-GAAP results and cash flow in separate roles, allowing each to answer the question it is suited to answer.

07 Cash generation: software investment changes the free-cash-flow reading

At June 30, 2026, Certara reported $184.138 million of cash and cash equivalents. First-half cash provided by continuing operating activities was $15.584 million. The cash-flow statement also reports $13.223 million of capitalized software development and $1.252 million of capital expenditures. Subtracting those two investing outflows from continuing operating cash flow gives a calculated $1.109 million residual for the half. This is an analytical cash measure, not a company-reported non-GAAP figure, and it should not be confused with total consolidated operating cash flow. Source: Q2 Sec.

The calculation illustrates why capitalized software deserves attention. Product development can be economically necessary even when accounting rules place part of the cash outflow in investing activities. Looking only at operating cash flow can therefore overstate the amount available after maintaining and improving the software portfolio. The opposite extreme would also be wrong: treating every development dollar as waste would ignore the investment needed to keep a scientific product useful and competitive. The question is whether the investment earns an adequate return over time.

The sale proceeds also need to be separated from recurring cash generation. Cash received for a disposed business strengthens the balance sheet at the time of the transaction, but it is not a repeatable operating inflow. A company can report a healthy ending cash balance while its retained operations produce relatively little cash after investment. That does not necessarily indicate distress, but it changes how repurchases, debt reduction and acquisitions should be evaluated. Capital allocation should be supported by the future cash capacity of the retained company, not only by one transaction’s proceeds.

Working capital can make a half-year result uneven. Collections, billing schedules, accrued compensation and other timing factors can shift cash between periods. This hub does not extrapolate the calculated first-half residual into a permanent annual rate. Instead, it identifies the cash items that a later update should reconcile. A stronger second half could materially change the annual picture; another period of limited conversion would reinforce the need for caution when interpreting adjusted earnings.

A clear future disclosure would connect revenue growth, operating cash flow, capitalized development and financing uses. If software growth accelerates while development spending remains productive, the cash economics could improve. If spending rises but adoption does not, the balance-sheet cost of the strategy becomes more important. The company’s technology should therefore be assessed as both an asset and an ongoing investment commitment. Cash generation after that commitment is a practical test of whether the software proposition is creating distributable economic value.

08 Debt, liquidity and the choices available to management

The debt note reports $294.028 million of term-loan principal at June 30, 2026. After debt issuance costs, total carrying value was $291.839 million, including a $2.963 million current portion. No revolver borrowing was shown at that date. These figures should be kept distinct from the cash balance and from lease liabilities. A company can have significant cash and still carry meaningful leverage; subtracting cash from principal is a different measure from quoting net balance-sheet debt after accounting discounts. Source: Q2 Sec.

Debt creates a fixed financing burden and can constrain choices through contractual provisions. It can also be a reasonable part of a capital structure when a business produces reliable cash. The analytical issue is the relationship between obligations and the cash capacity of the retained company after the disposal. A balance-sheet snapshot alone cannot establish that relationship. It must be combined with operating performance, interest costs, investment requirements and management’s intended uses of capital.

Interest-rate exposure also needs to be interpreted with the hedging disclosures. The filing describes interest-rate swaps used to manage exposure associated with the term loan. A headline market-rate movement does not necessarily translate one-for-one into the company’s interest expense. Equally, a hedge does not eliminate principal repayment or every financing risk. Readers should distinguish the contractual borrowing rate, the effect of derivatives and the accounting presentation of financing costs rather than assuming a single floating-rate number explains the whole position.

The disposal proceeds create choices. Management could use capital for debt reduction, product investment, acquisitions, repurchases or a combination. Each option has a different risk and return profile. Paying down debt can reduce financing burden; product spending can support future competitiveness; repurchases can increase each remaining share’s participation if executed at attractive economics. None is automatically superior without assumptions about the business and price. The existence of several options is useful, but disciplined selection is what creates value.

The next balance-sheet review should therefore examine not just the amount of cash but how it changed. A stable cash balance funded by recurring operations has a different meaning from one supported by asset sales while repurchases and acquisitions consume cash. The company is not analyzed here with a clinical-stage cash-runway formula. It has an established revenue business and positive operating cash flow, but it also has debt and product investment needs. The relevant question is the quality and flexibility of that cash generation, not an invented date when the cash will run out.

09 Repurchases, equity compensation and the per-share result

The August 4 release says Certara completed its previously authorized $100 million share-repurchase program and that the board authorized an additional $50 million. An authorization is permission to repurchase up to a specified amount; it is not proof that the full amount has already been spent. The cash-flow statement and subsequent disclosures are needed to establish actual purchases. This distinction matters because announced capacity can attract attention even when the timing and amount of execution remain discretionary. Sources: Q2 Release, Q2 Sec.

Repurchases can improve per-share measures by reducing shares outstanding, but they do not increase total customer demand or operating cash generation. They can be economically attractive when the company buys shares below a reasonable estimate of value and retains enough flexibility for operations and investment. They can be less attractive if undertaken at poor prices or while debt and product needs deserve priority. The hub does not infer that a buyback authorization is a management-issued price floor or a guarantee of future returns.

The cover of the June-quarter filing reports 152,538,780 common shares outstanding on August 1, 2026. The point-in-time count is not the same as weighted-average shares used for earnings per share. It also should not be confused with management’s fully diluted share guidance. Equity compensation, repurchases and the timing of transactions can make the measures differ. A valuation calculation should state which count is used and why, rather than selecting whichever denominator produces the most favorable multiple. Source: Q2 Sec.

Equity compensation is another reason to examine the full bridge. Repurchases can offset issuance to employees, reduce the total count, or do both. The economic result depends on the gross shares issued, the shares retired, the cost paid and the value created by employee work. Describing all repurchases as capital returned to shareholders without considering issuance can overstate the reduction in ownership dilution. Conversely, equity awards can be a useful compensation tool if aligned with long-term performance. The assessment requires evidence, not a blanket conclusion.

A useful later update would show the ending count, the average purchase price, total cash spent and the relationship to operating cash generation. It would also explain whether the company’s growth and margin goals are translating into improved results per share. A lower denominator can support EPS during a period of weak growth, but it cannot indefinitely substitute for better operating performance. Shareholder value depends on both sides of the equation: the business’s future cash flows and the number of claims on them.

10 Organizational change: focus, savings and execution risk

The August results update describes a reorganization around Model Informed Discovery and Drug Development, or MID3, and Accelerated Clinical Evidence, or ACE. It also describes a workforce reduction affecting approximately 5% of the global employee base and expected run-rate savings of about $13 million from the action and other operating measures. These are company disclosures and targets. The expected savings should not be presented as cash already realized in full during the quarter. Source: Q2 Release.

Organizational changes can improve accountability when products and customers have previously been spread across a complex structure. They can clarify where investment belongs and how sales teams coordinate. They can also disrupt relationships, consume management attention and create transition costs. The announcement of a simpler structure therefore supports a plausible strategy but does not establish its success. The success test is whether customers experience better service and whether the financial results show the intended benefits without impairing growth.

Stranded costs are particularly relevant after a disposal. Some corporate expenses may remain even though a business has left the consolidated revenue base. Removing or reallocating those costs can take time. This helps explain why the retained company’s economics may not immediately reflect the final structure. However, a prolonged transition should not become an indefinite explanation for weak performance. Future disclosures should identify what has been completed and how much of the expected improvement is visible in actual costs.

Leadership changes form part of the same execution picture. The June 17 SEC filing records the chief financial officer’s planned departure and the appointment of Faiz Mohammed as interim CFO in July 2026. The August release identifies Julien Perrier as chief commercial officer. These appointments are dated developments, not evidence by themselves that financial or sales execution will improve. Their relevance lies in the responsibilities they oversee and the operating results that follow. Sources: Cfo, Q2 Release.

A balanced reading neither dismisses the transformation as cosmetic nor credits all projected benefits in advance. The retained company needs to show that its sales approach, product roadmap and cost base fit together. A reduction in overhead could be constructive if it preserves scientific capability and customer support. It could be counterproductive if it weakens delivery or slows innovation. The most useful evidence will come from comparable growth, bookings, margins and customer outcomes over several periods, with a clear bridge from the old structure to the new one.

11 Artificial intelligence and product innovation: adoption must follow announcements

Certara’s July 7, 2026 announcement described work with NVIDIA’s BioNeMo Agent Toolkit to connect its scientific software, data and expertise with AI-driven agents. This is a product and technology development disclosure. It does not establish a separately quantified revenue contribution, a guaranteed commercial contract value or a completed transformation of the company’s business model. The distinction is important because an association with a prominent technology provider can affect market attention before financial evidence is available. Source: Ai.

The plausible opportunity is to make complex scientific workflows easier to use and to help researchers move between relevant tools and information. If an interface reduces friction while preserving scientific rigor, it could expand use or improve customer productivity. But an AI-generated answer in a regulated development context still needs traceability, validation and expert interpretation. Fluency is not the same as correctness. A product that supports consequential scientific decisions must make it possible to understand the evidence and limitations behind its output.

Commercial adoption also depends on practical considerations. Customers need to assess data security, integration, cost, usability and whether a new capability improves decisions enough to justify deployment. A demonstration can show technical possibility without resolving those purchasing questions. The same is true of broad industry interest in AI. That interest creates an opportunity for vendors, but it does not identify which vendor will capture the economics or how quickly revenue will appear.

For Certara, the strongest case is that AI makes its existing scientific assets more useful rather than replacing the need for those assets. Models, validated workflows, curated information and domain expertise can provide context that a general-purpose system lacks. The risk is that new interfaces make some tasks easier to commoditize or that development costs rise before customers are willing to pay. Both possibilities belong in the analysis. Neither can be settled solely by the announcement of a collaboration or toolkit integration.

The next evidence should be concrete: product availability, adoption by identifiable customer groups, changes in usage or retention, and financial contribution if the company discloses it. This hub does not assign an AI revenue number or valuation premium. It treats the initiative as a potential improvement to the product proposition whose economic importance remains to be demonstrated. That approach allows the analysis to recognize innovation without converting a technology announcement into an unsupported earnings forecast.

12 Guidance and operating milestones: the calendar is financial, not binary

The August 4 outlook calls for 2026 continuing-operations revenue of $367 million to $382 million, representing growth of 0% to 4% on the comparable basis. It also gives an adjusted EBITDA margin range of approximately 29% to 31% and adjusted diluted EPS of $0.31 to $0.36. Management’s fully diluted share assumption is 155 million to 157 million. These are dated company forecasts, not completed results. They should be refreshed when the company issues a later outlook. Source: Q2 Release.

The revenue range is particularly useful because it anchors the current discussion in modest expected growth. A long-term aspiration for stronger growth can coexist with a cautious near-term forecast, but the two should not be merged. The current-year guidance describes management’s expectation for the ongoing business after the disposal. A claim that Certara is already delivering sustained double-digit growth would not be supported by this outlook or the reported quarter. The transition remains a task for management to execute.

The next financial results will help test whether software strength and improving services, as anticipated by management, are appearing in the numbers. A confirmed release date should come from the investor-relations calendar or a company announcement. This edition does not infer an exact date from prior-year timing. The event of interest is the next operating report and any guidance revision; a calendar estimate is not a company commitment.

Several milestones can be monitored without treating them as binary catalysts. Software bookings can indicate demand before revenue recognition. Services bookings and utilization can help explain the direction of delivery. The cost base can show whether restructuring benefits are emerging. Capitalized development and cash flow can show the investment required to support the strategy. None of these measures is complete by itself. Together, they provide a more reliable picture of the business than an isolated earnings headline.

Guidance should also be checked for scope and definitions. A change in adjusted EPS can reflect share assumptions as well as operations. A margin range can change after a disposal even if the underlying retained business is unchanged. A revenue comparison can be affected by currency or classification. The appropriate response is to reconcile the new guide to the old one, identifying what is operational and what is mechanical. That prevents apparent improvements or deteriorations from being misread when the reporting perimeter has changed.

13 Valuation, market positioning and the next decision-relevant evidence

The dated market reference is a $9.13 close on October 9, 2026, with 5,035,125 shares of daily volume in the Alpaca SIP daily bar. This is a historical session value, not a real-time quote or an average-liquidity estimate. The external Finviz chart can update independently of the report. The verified share count comes from an earlier filing date, so this hub does not present a supposedly current market capitalization derived from mismatched dates. Source: Market.

A valuation framework should distinguish software economics, services economics and the effects of acquisitions and divestitures. Applying a pure software multiple to the entire business can ignore the labor and project characteristics of services. Applying a generic consulting multiple can understate the potential value of proprietary scientific products. The right approach requires explicit assumptions about mix, growth, margins, retention and reinvestment. Those assumptions should be visible rather than hidden inside a single comparison with an unrelated company.

The most important accounting bridge is from adjusted EBITDA to cash after development investment. A multiple based on adjusted EBITDA can be useful for comparisons, but it is incomplete if recurring investment and equity compensation differ significantly across companies. Likewise, a low multiple does not establish undervaluation if the earnings base is declining, and a high multiple does not prove overvaluation if growth and cash economics improve. The market price needs to be evaluated against a coherent operating model, not against a label such as biosimulation or AI.

No independently reconciled analyst-consensus target, current short-interest ratio or institutional-ownership percentage is included in this edition. This is a disclosure about the limits of the evidence collected, not an assertion that those datasets do not exist. An analyst target should retain its date, issuing firm and assumptions; ownership filings have reporting lags; and short interest requires a settlement date. Adding stale or methodologically inconsistent numbers would make the hub look more complete while reducing its reliability.

The next meaningful evidence is whether the retained company begins to show better growth and cash conversion at the same time. A services recovery supported by bookings, continued software demand and realized cost savings would strengthen the case. Persistent weak growth, recurring exceptional costs or capital allocation that outruns operating cash generation would weaken it. Certara has a scientifically relevant business and a clear opportunity to improve execution. The report’s conclusion remains conditional on that improvement appearing in results, and it does not recommend buying, selling or holding the stock.

Frequently asked questions about $CERT

Is Certara a drug developer with a PDUFA catalyst? Certara sells software and technology-enabled services used in drug discovery and development. It is exposed to customer research activity, but this hub does not identify a Certara-owned drug awaiting an FDA marketing decision. Its near-term milestones concern demand, product adoption, organizational execution and financial performance. Assigning it a therapeutic PDUFA date would misdescribe the business and create an event that is not supported by the sources. Annual Sec

Why are there two different Q2 loss figures? The $6.1 million loss refers to continuing operations. The $55.270 million consolidated net loss includes discontinued operations and the effect of selling Regulatory and Medical Writing. The two numbers answer different questions: the first helps evaluate the retained business, while the second describes the total GAAP result for the quarter. A reliable comparison preserves the scope and uses the corresponding prior-period measure. Q2 Sec Q2 Release

Is the new repurchase authorization already spent? An authorization gives management capacity to repurchase shares under stated conditions; it is not an executed purchase. Certara announced completion of its earlier program and an additional authorization in August. Actual subsequent spending requires the relevant filings. A repurchase can change per-share economics, but it does not create customer demand or guarantee a share-price floor. Its value depends on price, funding and competing capital needs. Q2 Release

Why does capitalized software matter to cash flow? Some software development cash is reported in investing activities. It remains an economic use of cash even though it is not deducted within operating cash flow. Comparing operating cash alone with adjusted EBITDA can therefore miss part of the investment needed to support the product portfolio. The report separates continuing operating cash, capitalized development and capital expenditure before discussing the residual available for other uses. Q2 Sec

Does the NVIDIA initiative establish new revenue? The July announcement describes a technology collaboration and intended capabilities. It does not provide a separately quantified revenue contribution in the evidence reviewed here. The commercial test is subsequent adoption, customer value and financial disclosure. AI could make scientific workflows more useful, but the benefits depend on validation, integration and willingness to pay. The announcement is a development milestone rather than proof of an earnings contribution. Ai

What does the Health Score tell a reader? It summarizes an editorial view of financial and operating resilience across five weighted pillars. It is not a target price, analyst consensus or instruction to trade. The score can change when new evidence changes the assessment. It should be read alongside the underlying reasons, particularly the distinction between cash held, recurring cash generated, debt obligations and the investment needed to sustain the software business.